Sun Hee Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sun Hee Lee has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Scott H. Kaufmann
Department of Oncology, Mayo Clinic, Rochester, USA
2 shared publications - Alexander Koenig
Department of Comparative Human Development University of Chicago Chicago Illinois USA
1 shared publication Amanika Kumar
Division of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN
1 shared publication- Aminah Jatoi
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Andrea Elisabeth Wahner Hendrickson
Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN
1 shared publication Andrea Mariani
Division of Gynecologic Oncology Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
PURPOSE: To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS: This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS: A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION: In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (1)
Open AccessLong-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
PURPOSE: To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS: This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS: A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION: In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
- Open Access
- 28 April 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (5) , 101980
Correction: High cell surface death receptor expression determines type I versus type II signaling
- 28 April 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (5) , 101980
Open AccessCorrection: High cell surface death receptor expression determines type I versus type II signaling
- Open Access
- 14 January 2009
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- No. 10,p. 1240-1242
Switchable redox activity by proton fuelled DNA nano-machines
The switching electrochemical property of an SWNT/DNA hybrid can be produced through reversible conformational changes between the closed and open state originating from the pH-responding i-motif DNA which significantly improves its molecular switching and stability by hydrophobic interactions with SWNTs.
- 14 January 2009
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- No. 10,p. 1240-1242
Open AccessSwitchable redox activity by proton fuelled DNA nano-machines
The switching electrochemical property of an SWNT/DNA hybrid can be produced through reversible conformational changes between the closed and open state originating from the pH-responding i-motif DNA which significantly improves its molecular switching and stability by hydrophobic interactions with SWNTs.
- 6 February 2001
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 81 (1) , 93-101
Role of pertussis toxin-sensitive G-proteins in intracellular Ca2+ release and apoptosis induced by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) Cl? channels in HepG2 human hepatoblastoma cells
Previously, we have reported that inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl− channels by glibenclamide induced intracellular Ca2+ release from IP3‐sensitive stores and apoptosis in HepG2 human hepatoblastoma cells (Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS. 1999 . Biochem Biophys Res Commun 261:682–688). In this study we investigated the upstream signals involved in the mechanism of these actions of glibenclamide. Treatment with glibenclamide initiated production of inositol 1,4,5‐trisphosphate (IP3) in a dose‐ and time‐dependent manner. The glibenclamide‐induced formation of IP3 was significantly inhibited by CFTR activators (levamisole and bromotetramisole). The intracellular Ca2+ release and apoptosis induced by glibenclamide were significantly suppressed by treatment with phospholipase C (PLC) inhibitors (U‐73122 and manoalide) or by pretreatment with pertussis toxin (PTx). In addition, PTx‐catalyzed ADP‐ribosylation of GTP‐binding proteins (G‐proteins) was markedly enhanced by treatment with glibenclamide in a time‐dependent manner. Taken together, these results suggest that PTx‐sensitive G‐proteins coupled to PLCβ may mediate the intracellular Ca2+ release and apoptosis induced by inhibiting CFTR Cl− channels in HepG2 cells. These results further suggest that the PTx‐sensitive G‐proteins may be a valuable target for the therapeutic intervention of human hepatomas. J. Cell. Biochem. 81:93–101, 2001.
- 6 February 2001
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 81 (1) , 93-101
Role of pertussis toxin-sensitive G-proteins in intracellular Ca2+ release and apoptosis induced by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) Cl? channels in HepG2 human hepatoblastoma cells
Previously, we have reported that inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl− channels by glibenclamide induced intracellular Ca2+ release from IP3‐sensitive stores and apoptosis in HepG2 human hepatoblastoma cells (Kim JA, Kang YS, Lee SH, Lee EH, Yoo BH, Lee YS. 1999 . Biochem Biophys Res Commun 261:682–688). In this study we investigated the upstream signals involved in the mechanism of these actions of glibenclamide. Treatment with glibenclamide initiated production of inositol 1,4,5‐trisphosphate (IP3) in a dose‐ and time‐dependent manner. The glibenclamide‐induced formation of IP3 was significantly inhibited by CFTR activators (levamisole and bromotetramisole). The intracellular Ca2+ release and apoptosis induced by glibenclamide were significantly suppressed by treatment with phospholipase C (PLC) inhibitors (U‐73122 and manoalide) or by pretreatment with pertussis toxin (PTx). In addition, PTx‐catalyzed ADP‐ribosylation of GTP‐binding proteins (G‐proteins) was markedly enhanced by treatment with glibenclamide in a time‐dependent manner. Taken together, these results suggest that PTx‐sensitive G‐proteins coupled to PLCβ may mediate the intracellular Ca2+ release and apoptosis induced by inhibiting CFTR Cl− channels in HepG2 cells. These results further suggest that the PTx‐sensitive G‐proteins may be a valuable target for the therapeutic intervention of human hepatomas. J. Cell. Biochem. 81:93–101, 2001.